Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 50-54

  Hale, Sharon L ^a   Kloner, Robert A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fibrin; Infarct size; No reflow phenomenon; Rabbit

Indexed keywords

DABIGATRAN; HEMOGLOBIN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NO REFLOW PHENOMENON; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; MALE; MYOCARDIAL REPERFUSION INJURY; NO-REFLOW PHENOMENON; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT;

ANIMALS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DISEASE MODELS, ANIMAL; MALE; MYOCARDIAL REPERFUSION INJURY; NO-REFLOW PHENOMENON; RABBITS;

EID: 84921361946     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1098-x     Document Type: Article

References (25)

1. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K (2005) Epicardial and microvascular reperfusion with primary percutaneous coronary intervention. Ital Heart J 6:447–452
2. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R (2007) Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on 6-month mortality. Am J Cardiol 99:442–445
3. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T (2000) Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36:1202–1209
4. Zhang ZG, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C, Ho KL (1999) Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 19:10898–10907
5. Kloner RA, Ganote CE, Jennings RB (1974) The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54:1496–1508
6. Reffelmann T, Kloner RA (2002) The “no-reflow” phenomenon: basic science and clinical correlates. Heart 87:162–168
7. Mak KH (2012) Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2(5):e001592. doi:10.1136/bmjopen-2012-001592
8. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402
9. Hale SL, Kloner RA (1997) Myocardial temperature in acute myocardial infarction: protection with mild regional hypothermia. Am J Physiol 273:H220–H227
10. Hale SL, Kloner RA (2010) Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/reperfusion in the rabbit. J Cardiovasc Pharmacol Ther 15:60–67
11. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 5:1237–1242
12. Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156
13. Nanobashvili J, Neumayer C, Fuegl A, Blumer R, Prager M, Sporn E, Polterauer P, Malinski T, Huk I (2003) Development of ‘no-reflow’ phenomenon in ischemia/reperfusion injury: failure of active vasomotility and not simply passive vasoconstriction. Eur Surg Res 35:417–424
14. Vrints CJ (2009) Pathophysiology of the no-reflow phenomenon. Acute Card Care 11:69–76
15. Widgerow AD (2014) Ischemia-reperfusion injury: influencing the microcirculatory and cellular environment. Ann Plast Surg 72:253–260. doi:10.1097/SAP.0b013e31825c089c
16. Kloner RA, Ganote CE, Jennings RB, Reimer KA (1975) Demonstration of the “no-reflow” phenomenon in the dog heart after temporary ischemia. Recent Adv Stud Cardiac Struct Metab 10:463–474
17. Wohrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, Stone GW (2012) Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy. Catheter Cardiovasc Interv 79:1083–1089
18. Gerotziafas GT, Galea V, Mbemba E, Sassi M, Roman MP, Khaterchi A, van DP, Japcowitz M, Lotz JP, Bernaudin JF, Fareed J, Hatmi M, Elalamy I (2012) Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3. Curr Vasc Pharmacol [Epub ahead of print]
19. Macchi L, Moussa WB, Guillou S, Tamareille S, Lamon D, Prunier D, Prunier F (2014) The synthetic pentasaccharide fondaparinux attenuates myocardial ischemia-reperfusion injury in rats via STAT-3. Shock 41:166–171
20. Chong AJ, Pohlman TH, Hampton CR, Shimamoto A, Mackman N, Verrier ED (2003) Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg 75:S649–S655
21. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C (2012) Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 31:330–339
22. Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112:1973–1979
23. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 125:669–676
24. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61:2264–2273
25. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J (2013) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 35:295–301